Avistone Pharmaceuticals Secures $200 Million Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital

Investment to Support Business Combination with Pearl Biotechnology to Create Leading Targeted Oncology Platform Combined Company Has Broad Pipeline Focused on Treatments for Lung Cancer, Including Two Drug Candidates in Advanced Clinical Developm...

Full "IntellAsia: Resources" article